Dyax expands research accord with Trubion

Massachusetts, USA-based Dyax Corp says that Trubion Pharmaceuticals has exercised an option to expand its existing research agreement, which covers protein therapeutics and diagnostics discovery. In addition to the ongoing multiple-target funded research project, Dyax will now transfer its proprietary phage library to Trubion's facility for use in identifying therapeutic leads to additional targets, further enabling the latter's ability to rapidly design and develop product candidates for a range of disease targets. Financial terms of the expanded agreement were not disclosed.

Henry Blair, chief executive of Dyax, commented: "this expanded agreement continues to validate our technology as a powerful tool for accelerating discovery and development of therapeutic agents and, additionally, confirms the success of our licensing and funded research program."